HLN Stock Analysis: Buy, Sell, or Hold?
HLN - Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$9.23
0.28 (3.13%)
▲
5d:
+1.54%
30d:
-0.65%
90d:
-4.85%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When HLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HLN shows positive signals but monitor for confirmation. Market pricing in 4.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: HLN shows positive signals but monitor for confirmation. Market pricing in 4.4% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.18
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$8.80
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HLN is currently trading at $9.23, which is considered extended relative to its 30-day fair value range of $8.88 to $9.24. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.7) compared to its historical average (16.8). Remarkably, the market is currently pricing in an annual earnings decline of 4.4% over the next few years. This pessimistic expectation contrasts with the company's recent 92.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is approaching resistance at $9.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: HLN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.69 (+30.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is approaching resistance at $9.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: HLN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.69 (+30.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.88 -
$9.24
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 30.6% below Wall St target ($11.69)
Trading Range Analysis
30-Day Trading Range
$8.88 -
$9.24
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.77
Resistance Level
$9.28
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.69
Wall Street Target
$11.69
(+30.6%)
Revenue Growth (YoY)
0.6%
Earnings Growth (YoY)
92.0%
Profit Margin
15.1%
Valuation Discount vs History
-4.4% cheaper
PE vs Historical
14.7 vs 16.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.4%
(market-implied from PE analysis)
1-Year Target
$8.56
(-4%)
2-Year Target
$8.18
(-9%)
3-Year Target
$7.82
(-13%)
3-Yr Target (if PE normalizes)
(PE: 15→17)
$8.94
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 9.5%)
$17.45
(+95%)
Base:
(SPY PE: 14.7, Growth: 9.5%)
$11.77
(+32%)
Bear:
(PE: 12.5, Growth: 9.5%)
$10.00
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 17.90 | Current EPS (TTM): $0.49
Bull Case
$12.00
(+34%)
Analyst growth 24.3%, PE expands to 19.7
Base Case
$10.91
(+22%)
Market implied 24.3%, PE stable at 17.9
Bear Case
$5.96
(-33%)
Severe decline -20.0%, PE contracts to 15.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.7 to 16.8
Stabilization Target:
$10.24
(+14.4%)
PE Expansion Potential:
+14.4%
Share & Embed Analysis
Last updated: June 24, 2026 4:18 PM ET
Data refreshes hourly during market hours. Next update: 5:18 PM
Data refreshes hourly during market hours. Next update: 5:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
